IDT combines with 454 in worldwide primer pact
This article was originally published in Clinica
Executive Summary
Roche’s DNA sequencing subsidiary 454 Life Sciences has signed an exclusive co-promotional agreement with nucleic acids specialist Integrated DNA Technologies (IDT). The deal, of which specific financial details were not revealed, will see Coralville, Iowa-based IDT use its online design tool to design, synthesize and purify fusion primers for certain 454 sequencing applications. These applications include sequencing technology for the detection of low-frequency mutations in disease-associated genes, and identification and quantification of common and rare variants within a population.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals